Evaluating the antifracture efficacy of bisphosphonates.
Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...
Main Authors: | Pazianas, M, Epstein, S, Zaidi, M |
---|---|
格式: | Journal article |
語言: | English |
出版: |
2009
|
相似書籍
-
Antifracture agents for prostate cancer patients on androgen deprivation therapy
由: Bhupendra P Singh, et al.
出版: (2010-01-01) -
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
由: Angelo Fassio, et al.
出版: (2024-04-01) -
Safety of bisphosphonates.
由: Pazianas, M, et al.
出版: (2011) -
Bisphosphonates and bone quality.
由: Pazianas, M, et al.
出版: (2014) -
Atrial fibrillation and bisphosphonate therapy.
由: Pazianas, M, et al.
出版: (2010)